Indications
Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
Composition
- Active substance
- eslicarbazepine acetate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Exalief
- Active substance
- eslicarbazepine acetate
- ATC code
- N03AF04
- Group
- Nervous system
- Therapeutic area
- Epilepsy
- Marketing authorisation holder
- BIAL - Portela Ca, S.A.
- Status
- Lapsed
- EU authorisation
- 21 Apr 2009
- Withdrawn
- 24 Jul 2012